Rapamycin injections tested for safety and efficacy in treatment-naive age-related macular degeneration: Phase 1/2 RCT
A Phase 1/2 randomized controlled trial evaluated sirolimus (rapamycin) administered via different injection routes in patients with newly diagnosed, treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration. The study assessed safety and efficacy outcomes, though specific effect sizes and patient numbers were not reported in the provided abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jan 10, 2013 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with newly diagnosed, treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Primary outcome
- Safety and efficacy of ocular sirolimus formulation
- Effect size
- —
- Significance
- Not reported
- Journal
- Santen Inc.
- Published
- Jan 10, 2013
Sources
Primary source
- Santen Inc. ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.